Emily Shutman's questions to Zymeworks Inc (ZYME) leadership • Q2 2025
Question
Emily Shutman of Leerink Partners inquired about the upcoming HORIZON-GEA-01 trial readout, asking if PD-L1 status would be detailed in the top-line results and seeking clarity on the allocation of the remaining $500 million in regulatory milestones from partner Jazz Pharmaceuticals.
Answer
President, CEO & Chairman Kenneth Galbraith explained that the content of the top-line data release is at the discretion of partners Jazz and B1. He also stated that Zymeworks has not provided specific guidance on how the remaining $500 million in development milestones is allocated across various indications.